Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448

Abstract

BackgroundTriple negative breast cancers (TNBC) possess cell dedifferentiation characteristics, carry out activities connate to those of cancer stem cells (CSCs) and are associated with increased metastasis, as well as, poor clinical prognosis. The regulatory mechanism of this highly malignant phenotype is still poorly characterized. Accruing evidence support the role of non-coding RNAs (ncRNAs) as potent regulators of CSC and metastatic gene expression, with their dysregulation implicated in tumorigenesis and disease progression.MethodsIn this study, we investigated TNBC metastasis, metastasis-associated genes and potential inhibitory mechanisms using bioinformatics, tissue microarray analyses, immunoblotting, polymerase chain reaction, loss and gain of gene function assays and comparative analyses of data obtained.ResultsCompared with other breast cancer types, the highly metastatic MDA-MB-231 cells concurrently exhibited increased expression levels of Lysine-specific demethylase 5B protein (KDM5B) and long non-coding RNA (lncRNA), MALAT1, suggesting their functional association. KDM5B-silencing in the TNBC cells correlated with the upregulation of hsa-miR-448 and led to suppression of MALAT1 expression with decreased migration, invasion and clonogenic capacity in vitro, as well as, poor survival in vivo. This projects MALAT1 as a mediator of KDM5B oncogenic potential and highlights the critical role of this microRNA, lncRNA and histone demethylase in cancer cell motility and metastatic colonization. Increased expression of KDM5B correlating with disease progression and poor clinical outcome in breast cancer was reversed by hsa-miR-448.ConclusionsOur findings demonstrate the critical role of KDM5B and its negative regulator hsa-miR-448 in TNBC metastasis and progression. Hsa-miR-448 disrupting KDM5B-MALAT1 signalling axis and associated activities in TNBC cells, projects it as a putative therapeutic factor for selective eradication of TNBC cells.Graphical abstractKDM5B, MALAT1 and hsa-miR-448 are active looped components of the epigenetic poculo mortis in aggressive breast cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2108-5) contains supplementary material, which is available to authorized users.

Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report

“…EZH2 is an aggressive BCC marker, and while higher JARID1B expression trends towards aggressive versus less aggressive tumors (H-score: 0.762 versus 0.650), respectively, the difference was not found to be statistically significant ( p = 0.39). Analysis of a larger number of BCC cases may reveal a statistically significant association between JARID1B expression and histological type, as has been observed in other tumors such as triple-negative breast cancer [11]. Our data suggest associations between certain histone methylases, demethylases, acetyltransferases and DNA hydroxymethyl marks.…”

Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer

“…Jin et al demonstrated a reciprocal negative control relationship between MALAT1 and miR-1; MALAT1 might exert its function through the miR-1/slug axis [27]. Bamodu et al identified MALAT1 as a mediator of KDM5B oncogenic potential in triple-negative breast cancer, and could be reversed by hsa-miR-448 [30]. Furthermore, MALAT1 reversed the inhibitory effect of miR-124 on breast cancer proliferation and was involved in the cyclin-dependent kinase 4 (CDK4) expression [29].…”

NEAT1 contributes to breast cancer progression through modulating miR‐448 and ZEB1

“…Tumor‐suppressive gene miR‐452 can inhibit breast cancer cell development by directly binidng RAB11A (Li, Li, Fan, & Liu, ). miR‐448 is downregulated by KDM5B in aggressive breast cancer (Bamodu et al, ). However, the association between NEAT1 and miR‐448 remains uninvestigated in breast cancer.…”